Stressgen Biotechnologies signed a deal with Roche to co-develop and commercialize Stressgen’s proprietary product candidate, HspE7. Stressgen will grant a worldwide license to Roche to market and sell the product. The deal could be worth up to US$205 M if specific milestones and sales targets are met.